Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study
Biomolecules and Biomedicine · 2026
DOI: 10.17305/bb.2026.13678 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Biomolecules and Biomedicine, 2026. Verfasst von Yue Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Secon…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Circulating Tumor DNA, Colorectal Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Circulating tumor DNA (ctDNA) derived from blood samples can serve as a minimally invasive, real-time indicator of tumor burden and treatment response in metastatic colorectal cancer. This study evaluated the association between baseline ctDNA levels and changes in ctDNA during treatment with response and survival outcomes in the phase II ALTER-C-002 trial, which investigated first-line anlotinib combined with capecitabine and oxaliplatin in patients with rat sarcoma (RAS) and B-Raf proto-oncogene (BRAF) wild-type metastatic colorectal cancer. In this post-hoc biomarker analysis, plasma samples were collected at baseline, near the best radiologic response (C1), and at the timepoint closest to disease progression or last follow-up (C2). These samples were analyzed using a 90-gene next-generation sequencing (NGS) panel, with ctDNA abundance quantified as maximum somatic allele frequency (MSAF), where MSAF
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzho…
- State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China.
- Colorectal Surgery, Zhejiang University Jinhua Hospital, Jinhua, China.
- Colorectal Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
- Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Zitieren
APA
Liu, Y., He, J. J., Chen, S., Song, Y. J., Du, J. L., Zhu, Y. P., Chen, D. S., Deng, W. L., Yuan, Y., & Ding, K. F. (2026). Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2026.13678
Vancouver
Liu Y, He JJ, Chen S, Song YJ, Du JL, Zhu YP, et al. Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study. Biomolecules and Biomedicine. 2026. doi:10.17305/bb.2026.13678
BibTeX
@article{Liu2026,
author = {Liu, Yue and He, Jin-Jie and Chen, Sheng and Song, Yun-Jie and Du, Jin-Lin and Zhu, Yu-Ping and Chen, Dong-Sheng and Deng, Wang-Long and Yuan, Ying and Ding, Ke-Feng},
title = {Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study},
journal = {Biomolecules and Biomedicine},
year = {2026},
doi = {10.17305/bb.2026.13678}
}
EUVIMED